- Home
- FSEA vs ECOR Comparison
FSEA vs ECOR Comparison
Compare FSEA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSEA | ECOR |
|---|---|---|
| Founded | 1890 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 50.0M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FSEA | ECOR |
|---|---|---|
| Price | $12.91 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 3.9K | ★ 47.8K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 53.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,182,000.00 |
| Revenue This Year | N/A | $28.92 |
| Revenue Next Year | N/A | $32.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 57.09 |
| 52 Week Low | $10.13 | $4.16 |
| 52 Week High | $15.00 | $14.01 |
Technical Indicators
Market Signals| Indicator | FSEA | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 52.10 |
| Support Level | $11.44 | $4.64 |
| Resistance Level | $13.00 | $7.96 |
| Average True Range (ATR) | 0.14 | 0.77 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 0.00 | 53.60 |
Price Performance
Historical ComparisonAbout FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.